Clinuvel Pharmaceuticals Limited

DB:UR9 Stock Report

Market Cap: €361.3m

Clinuvel Pharmaceuticals Valuation

Is UR9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UR9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UR9 (€7.25) is trading below our estimate of fair value (€60.98)

Significantly Below Fair Value: UR9 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UR9?

Key metric: As UR9 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for UR9. This is calculated by dividing UR9's market cap by their current earnings.
What is UR9's PE Ratio?
PE Ratio16.8x
EarningsAU$35.64m
Market CapAU$598.86m

Price to Earnings Ratio vs Peers

How does UR9's PE Ratio compare to its peers?

The above table shows the PE ratio for UR9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average14.9x
FYB Formycon
15x22.6%€958.8m
BIO3 Biotest
15.6x29.3%€1.4b
2INV 2invest
13.4xn/a€67.3m
PSG PharmaSGP Holding
15.8x13.6%€297.4m
UR9 Clinuvel Pharmaceuticals
16.8x26.2%€598.9m

Price-To-Earnings vs Peers: UR9 is expensive based on its Price-To-Earnings Ratio (16.8x) compared to the peer average (14.9x).

Price to Earnings Ratio vs Industry

How does UR9's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
UR9 16.8xIndustry Avg. 29.0xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: UR9 is good value based on its Price-To-Earnings Ratio (16.8x) compared to the European Biotechs industry average (29x).

Price to Earnings Ratio vs Fair Ratio

What is UR9's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UR9 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.8x
Fair PE Ratio15.9x

Price-To-Earnings vs Fair Ratio: UR9 is expensive based on its Price-To-Earnings Ratio (16.8x) compared to the estimated Fair Price-To-Earnings Ratio (15.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UR9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€7.25
€16.92
+133.3%
38.2%€28.71€10.17n/a7
Dec ’25€8.05
€17.38
+115.9%
38.2%€29.49€10.44n/a7
Nov ’25€8.37
€17.30
+106.7%
38.2%€29.36€10.40n/a7
Oct ’25€9.12
€17.86
+95.9%
39.2%€29.40€10.41n/a6
Sep ’25€9.44
€17.86
+89.2%
39.2%€29.40€10.41n/a6
Aug ’25€8.91
€18.74
+110.4%
42.4%€29.66€9.89n/a6
Jul ’25€9.34
€16.62
+78.0%
41.4%€28.72€9.93n/a5
Jun ’25€9.62
€15.51
+61.3%
42.4%€28.05€9.69n/a5
May ’25€8.99
€15.51
+72.6%
42.4%€28.05€9.69n/a5
Apr ’25€8.76
€15.09
+72.3%
40.0%€27.93€9.65n/a6
Mar ’25€8.22
€15.09
+83.5%
40.0%€27.93€9.65n/a6
Feb ’25€9.24
€16.46
+78.1%
36.3%€29.17€10.97n/a6
Jan ’25€9.92
€16.45
+65.8%
38.9%€30.18€10.80€7.156
Dec ’24€10.90
€16.45
+50.9%
38.9%€30.18€10.80€8.056
Nov ’24€8.86
€18.72
+111.3%
36.3%€30.26€13.26€8.374
Oct ’24€9.03
€17.12
+89.6%
19.6%€21.38€13.17€9.123
Sep ’24€10.90
€17.12
+57.0%
19.6%€21.38€13.17€9.443
Aug ’24€10.89
€18.22
+67.4%
18.5%€22.33€14.08€8.913
Jul ’24€10.96
€18.49
+68.7%
19.1%€22.84€14.21€9.343
Jun ’24€11.14
€19.18
+72.2%
19.1%€23.70€14.75€9.623
May ’24€12.02
€19.18
+59.6%
19.1%€23.70€14.75€8.993
Apr ’24€12.00
€19.18
+59.9%
19.1%€23.70€14.75€8.763
Mar ’24€12.65
€19.18
+51.7%
19.1%€23.70€14.75€8.223
Feb ’24€15.55
€18.84
+21.2%
30.0%€25.13€11.43€9.243
Jan ’24€13.54
€17.71
+30.8%
31.1%€25.14€11.96€9.923

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 16:45
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Clinuvel Pharmaceuticals Limited is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas WakimBell Potter
Norbert KalliwodaDr. Kalliwoda Research
David StantonJefferies LLC